News

Dupixent (dupilumab) has been approved by the European Commission as an add-on maintenance treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). Specifically, the therapy from Sanofi and Regeneron Pharmaceuticals is now indicated for COPD patients in the European Union who have evidence of type…

The American Lung Association has launched the Wellness Hub, a resource designed to improve the everyday lives of people with chronic obstructive pulmonary disease (COPD) and other lung diseases. Wellness Hub content, including disease-specific online classes, live and on-demand webcasts, and educational resources for improving mental and physical health,…

The U.S. Food and Drug Administration (FDA) has approved Verona Pharma’s ensifentrine as an inhaled maintenance therapy for adults with chronic obstructive pulmonary disease (COPD). The decision makes ensifentrine — to be marketed under the brand name Ohtuvayre — the first therapy with a new mechanism of action…

One in six adults in the U.S. with chronic obstructive pulmonary disease (COPD) didn’t adhere to their medications due to costs, which is associated with a poor prognosis. That’s according to a study that analyzed data from a U.S. survey of adults with COPD between 2013-2020. Patients younger than…

Dupixent (dupilumab) as an add-on maintenance treatment significantly eased exacerbations and lung symptom severity while improving lung function and quality of life — among people with moderate to severe chronic obstructive pulmonary disease (COPD). That’s according to published data from the Phase 3 NOTUS clinical trial (NCT04456673), which…

The U.S. Food and Drug Administration (FDA) has delayed by three months its decision about whether to approve Dupixent (dupilumab) as an add-on treatment for certain adults with chronic obstructive pulmonary disease (COPD). A decision is now expected by Sept. 27. An initial call was due at the…

Tezepelumab, which is approved for severe asthma, tended to reduce the frequency of exacerbations in adults with moderate to very severe chronic obstructive pulmonary disease (COPD). That’s according data from the international, proof-of-concept Phase 2a COURSE clinical trial (NCT04039113) that included 337 COPD patients irrespective of emphysema, chronic…

Young adults who smoke or have smoked may halve their risk of developing emphysema — a form of chronic obstructive pulmonary disease (COPD) — by eating a nutritionally rich, plant-based diet, a new U.S. study suggests. The study, “A Plant-Centered Diet is Inversely Associated With Radiographic Emphysema: Findings…

The U.S. Food and Drug Administration (FDA) has asked for more data from clinical trials that tested Dupixent (dupilumab) in people with chronic obstructive pulmonary disease (COPD), Regeneron Pharmaceuticals, one of the therapy’s developers, announced during a company webcast. The requested data pertains to subgroup analyses from two…

A research team at The Lundquist Institute has been awarded a four-year grant to develop a wearable biosensor that can monitor continuously the risk of acute exacerbations by analyzing the sweat of people with chronic obstructive pulmonary disease (COPD). The grant, worth more than $2.6 million, was awarded by…